Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Immunoglobulin Light-chain Amyloidosis 1Glioma 1Colonic Neoplasms 1Breast Neoplasms 1Amyloidosis 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × Drug Evaluation × Clear all
NCT05189171 2024-06-28

MODEL-CRC

Xilis, Inc.

Completed
46 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00582660 2017-06-15

UAB0040

University of Alabama at Birmingham

Phase 2 Completed
40 enrolled 7 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡